AstraZeneca Discontinues Volrustomig Phase III Trial in First-Line Metastatic Non-Small Cell Lung Cancer
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.
